Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS, Janssen in Immuno-oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

BMS, Janssen in Immuno-oncology Alliance

Will evaluate Opdivo and Janssen drug in Phase II NSCLC trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb has entered a new clinical research collaboration with Janssen Biotech, Inc. to evaluate BMS’ immuno-oncology drug Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC).

Opdivois a human antibody designed to alleviate immune suppression. JNJ-64041757 is designed to induce an immune response against NSCLC tumors. The Phase II trial will evaluate the tolerability and clinical activity of the combination.

“We are excited to collaborate with Janssen as we explore how the emerging science of antigen-presentation therapeutics, in combination with Opdivo, can potentially provide a new treatment approach for patients with lung cancer,” said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics